10-Q: AbCellera Reports Q2 2026 Results, Revenue Down, Net Loss Widens

AbCellera Biologics Inc. announced its Q2 2026 financial results, showing a significant decline in total revenue and an increased net loss, while also highlighting progress in its clinical programs and new strategic partnerships.

Summary

• AbCellera Biologics Inc. reported a substantial decrease in total revenue for the second quarter of 2026, falling to $4.05 million from $17.08 million in the same period of 2025.
• The company experienced a net loss of $55.43 million for the three months ended June 30, 2026, an increase from a net loss of $34.73 million in the prior year's quarter.
• Research and development expenses increased by 17% to $45.99 million for the quarter, driven by clinical program costs.
• Sales, general, and administrative expenses decreased by 37% to $13.85 million, attributed to headcount optimization and a legal settlement.
• The company announced positive interim Phase 1 data for ABCL635 and completed enrollment for its Phase 2 study, with top-line data expected in August 2026.
• New collaborations were established with Jazz Pharmaceuticals PLC and Vertex Pharmaceuticals Inc., bringing in upfront payments of $56 million and $28 million, respectively.
• Total cash, cash equivalents, and marketable securities stood at $540.1 million as of June 30, 2026, with management expecting sufficient liquidity for at least the next 36 months.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to a significant decrease in revenue and a substantial increase in net loss, despite progress in clinical trials and new collaborations.

Positives

• Secured significant upfront payments totaling $84 million from new collaborations with Jazz Pharmaceuticals ($56 million) and Vertex Pharmaceuticals ($28 million).
• Announced positive interim Phase 1 data for ABCL635, showing potent and sustained reduction in biomarkers, a favorable tolerability profile, and pharmacokinetic data supporting monthly dosing.
• Completed enrollment for the Phase 2 study of ABCL635, with top-line data anticipated in August 2026.
• Reduced Sales, General, and Administrative (SG&A) expenses by 37% to $13.85 million, reflecting cost optimization efforts.
• Maintained a strong liquidity position with $540.1 million in cash, cash equivalents, and marketable securities, providing at least 36 months of operating runway.
• Advanced ABCL635 and ABCL575 into clinical trials, with ABCL688 and ABCL386 progressing into IND/CTA-enabling studies for anticipated 2027 Phase 1/2 trials.

Negatives

• Total revenue significantly decreased by 76% to $4.05 million in Q2 2026 compared to $17.08 million in Q2 2025, primarily due to a sharp drop in licensing and royalty revenue.
• Net loss widened to $55.43 million in Q2 2026 from $34.73 million in Q2 2025, indicating increased operational costs relative to revenue.
• Research and development expenses increased by 17% to $45.99 million, driven by clinical program costs, while revenue declined.
• Licensing and royalty revenue saw a dramatic decrease of 99% to $149,000 in Q2 2026 from $10.45 million in Q2 2025.
• The company continues to incur significant losses, with an accumulated deficit of $128.07 million as of June 30, 2026.

Risks

• The company has incurred losses since inception, including in 2025, and may not achieve profitability.
• Quarterly and annual operating results have fluctuated significantly and may continue to do so, making future results difficult to predict.
• Commercial success depends on the quality of antibody discovery and development capabilities, and the advancement and acceptance of internal programs.
• Failure to execute the business strategy could adversely impact growth and profitability.
• The development of drug candidates is uncertain, and none may receive marketing approval or become viable commercial drugs.
• Interim clinical trial data may change upon further review and audit.
• The company may not be able to file applications or commence additional clinical trials on expected timelines, or regulatory bodies may not permit them to proceed.
• The market price of common shares is volatile and could decline significantly due to clinical milestones or other factors.

Future Outlook

The company expects to continue making significant investments in research and development, advancing its internal pipeline, and enhancing its capabilities. Management believes its current liquidity is sufficient for at least the next 36 months. Future revenue is expected to be positively impacted by research fee recognition from recent collaborations with Jazz and Vertex.

Management Comments

• We think deeply about capital allocation and strive to maximize long-term value while mitigating the risks that are inherent in drug development.
• We look for opportunities where we believe low-risk investments in building technology and operational efficiency can create a sustained competitive advantage and drive long-term value by making antibody drug development faster and more efficient.
• We expect to continue to make significant investments in this area for the foreseeable future and expect to continue to incur significant expenses in connection with our ongoing activities.

Industry Context

StockSavvy.ai notes that AbCellera's performance reflects the high-risk, high-reward nature of the biotechnology sector. The significant increase in R&D spending is typical for companies advancing clinical-stage assets, while the revenue decline highlights the lumpy nature of licensing and royalty income in this industry. The new collaborations with Jazz and Vertex are positive developments, aligning with industry trends of strategic partnerships to de-risk drug development and leverage specialized capabilities.

Comparison to Industry Standards

• The increase in R&D spending as a percentage of revenue is higher than many established pharmaceutical companies but is within the typical range for clinical-stage biotech firms investing heavily in pipeline advancement.
• The net loss reported is substantial, but common for companies in this stage of development, where significant upfront investment is required before substantial revenue generation.
• The company's cash burn rate, while high in absolute terms, is supported by a substantial cash balance, which is a critical factor for survival and continued operations in the biotech industry.
• The strategic collaborations with Jazz and Vertex are standard practice in the industry to share risk and leverage partner expertise, particularly for companies like AbCellera focusing on early-stage discovery and development.

Legal Proceedings

• The company is involved in litigation with the Estate of John Schrader and ImmVivos Pharmaceuticals Inc., alleging breach of partnership and patent infringement. The company obtained consent for the invalidation of the Immvivos '511 patent and removal of infringement allegations, and believes the remaining claim is meritless.

Stakeholder Impact

• Shareholders may experience continued share price volatility due to clinical trial outcomes and financial performance.
• Employees may face uncertainty due to the company's ongoing losses, although cost optimization in SG&A could indicate a focus on efficiency.
• Partners (Jazz, Vertex) will benefit from AbCellera's discovery capabilities, while AbCellera gains upfront payments and potential future milestones/royalties.

Next Steps

• Await top-line data readout for the ABCL635 Phase 2 study, expected in August 2026.
• Continue advancing internal programs (ABCL688, ABCL386) into IND/CTA-enabling studies with anticipated Phase 1/2 trials in 2027.
• Recognize revenue from upfront payments received under the Jazz and Vertex collaborations.
• Monitor the progress of partner-led programs and potential milestone payments.
• Optimize long-term office-lease arrangements and potentially assign or sublease Beedie JV space.

Key Dates

Recommendation

While the company shows promising clinical development progress and secured significant new partnerships, the substantial increase in net loss and sharp decline in revenue are concerning. The strong cash position provides a buffer, but the path to profitability remains long and uncertain. Investors should hold positions while monitoring the ABCL635 Phase 2 data and the impact of new collaborations on future revenue.

Keywords

antibody discovery, drug development, clinical trials, biotechnology, biologics, pharmaceuticals, collaboration, licensing